Clinical trials: Intensive Care Unit Days
Conscious Sedation
Dexmedetomidine for Continuous Sedation
The study aims to demonstrate that dexmedetomidine is non-inferior to current best practice sedation with propofol/midazolam and daily sedation stops, in maintaining a target depth of sedation in long-stay intensive care unit…
- Trial name
- NCT00226785
- Testing
- Dexmedetomidine
- Where
- 4 sites in Finland, Switzerland
- Volunteers
- 900 people
- Sponsor
- Orion Corporation, Orion Pharma
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Analgesia
Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU)
This study will be a multicentre randomized, open-label, phase IIIb study. This study will evaluate two different techniques of sedation: an analgesia based regimen with remifentanil versus a conventional sedation based regimen…
- Trial name
- NCT00436345
- Testing
- Remifentanil, Propofol
- Where
- 6 sites in Italy
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline